Rhythm Pharmaceuticals (RYTM) Competitors $63.19 +0.46 (+0.73%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and VRNAShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, SMMT or RYTM? Summit Therapeutics has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Do analysts recommend SMMT or RYTM? Summit Therapeutics presently has a consensus price target of $35.09, indicating a potential upside of 64.90%. Rhythm Pharmaceuticals has a consensus price target of $77.31, indicating a potential upside of 22.34%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SMMT or RYTM more profitable? Summit Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Summit Therapeutics' return on equity of -62.87% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -62.87% -51.61% Rhythm Pharmaceuticals -123.26%-739.62%-44.27% Does the media prefer SMMT or RYTM? In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Rhythm Pharmaceuticals and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.82 beat Rhythm Pharmaceuticals' score of 0.43 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in SMMT or RYTM? 4.6% of Summit Therapeutics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, SMMT or RYTM? Summit Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Summit Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K22,577.17-$221.32M-$0.34-62.59Rhythm Pharmaceuticals$130.13M30.89-$260.60M-$2.81-22.49 SummarySummit Therapeutics beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.99B$2.84B$5.46B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-22.4921.1526.4419.67Price / Sales30.89259.51405.32110.29Price / CashN/A41.2925.8827.49Price / Book180.547.247.945.42Net Income-$260.60M-$55.05M$3.15B$248.34M7 Day Performance-0.74%-1.01%0.63%0.81%1 Month Performance2.98%5.98%4.96%5.01%1 Year Performance48.09%0.83%32.55%18.10% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.8732 of 5 stars$63.19+0.7%$77.31+22.3%+53.9%$3.99B$130.13M-22.49140SMMTSummit Therapeutics2.4834 of 5 stars$20.39-0.8%$35.09+72.1%+172.8%$15.27B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.9128 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9789 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.57B$3.12B11.752,682Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.8099 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.71B$3.81B23.2027,811ASNDAscendis Pharma A/S3.52 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.81B$393.54M-27.991,017VTRSViatris3.0162 of 5 stars$8.85-0.2%$10.40+17.5%-16.0%$10.41B$14.74B-2.7932,000QGENQiagen3.7171 of 5 stars$46.72-0.1%$47.74+2.2%+20.3%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.5255 of 5 stars$25.67-0.9%$46.61+81.6%-76.8%$10.02B$3.24B-2.945,800Trending NewsGap UpBPMCBlueprint Medicines1.7358 of 5 stars$128.40+0.2%$128.06-0.3%+18.9%$8.28B$508.82M-51.98640Positive NewsHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share1.6943 of 5 stars$97.05+2.9%$101.10+4.2%+554.1%$8.03B$42.28M-48.5330 Related Companies and Tools Related Companies Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Moderna Competitors Blueprint Medicines Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts